Narcan Naloxone Hci Spray
NDC Package 51662-1240-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Narcan Naloxone Hci sprays is nARCAN Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.NARCAN Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.NARCAN Nasal Spray is not a substitute for emergency medical care.Limitations of Use:Restrict prescription of NARCAN Nasal Spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. This formulation utilizes a spray delivery system. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1240 and is authorized under FDA application NDA208411.

Identification & Billing

NDC Package Code
51662-1240-2
Package Description
2 VIAL, SINGLE-DOSE in 1 PACKAGE / .1 mL in 1 VIAL, SINGLE-DOSE
Product Code
51662-1240
11-Digit Billing Format
51662124002
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Narcan Naloxone Hci
Non-Proprietary Name
Narcan Naloxone Hci
Substance Name
Naloxone Hydrochloride
Dosage Form
Spray - A liquid minutely divided as by a jet of air or steam.
Administration Route
Nasal - Administration to the nose; administered by way of the nose.
Active Ingredient(s)
NALOXONE HYDROCHLORIDE 4 mg/.1mL
Pharmacologic Class
Usage Information
NARCAN Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.NARCAN Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.NARCAN Nasal Spray is not a substitute for emergency medical care.Limitations of Use:Restrict prescription of NARCAN Nasal Spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts.

Regulatory & Marketing

Labeler Name
Hf Acquisition Co Llc, Dba Healthfirst
Product Type
Human Prescription Drug
FDA Application #
NDA208411
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
10-15-2018
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (51662-1240). Click a package code to view its specific billing and regulatory data.

51662-1240-1
.1 mL in 1 VIAL, SINGLE-DOSE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1240-2 identifies a specific commercial package of 2 vial, single-dose in 1 package / .1 ml in 1 vial, single-dose of Narcan Naloxone Hci, a human prescription drug labeled by Hf Acquisition Co Llc, Dba Healthfirst. This spray is formulated for nasal use and contains naloxone hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on October 15, 2018. The current certification is valid through December 31, 2026.

How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662124002. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1240-2
11-Digit CMS (5-4-2)
51662-1240-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.